These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 7834865

  • 1. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, Díaz-López JB, Cannata-Andía JB.
    Clin Chim Acta; 1994 Oct 31; 230(2):137-45. PubMed ID: 7834865
    [Abstract] [Full Text] [Related]

  • 2. Chelation of aluminium by combining DFO and L1 in rats.
    Blanusa M, Prester L, Varnai VM, Pavlović D, Kostial K, Jones MM, Singh PK.
    Toxicology; 2000 Jul 05; 147(3):151-6. PubMed ID: 10924797
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.
    Kontoghiorghes GJ.
    Toxicol Lett; 1995 Oct 05; 80(1-3):1-18. PubMed ID: 7482575
    [Abstract] [Full Text] [Related]

  • 4. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN, Kontoghiorghes GJ.
    Arzneimittelforschung; 1993 Jun 05; 43(6):659-63. PubMed ID: 8352819
    [Abstract] [Full Text] [Related]

  • 5. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity.
    Naves Díaz ML, Elorriaga R, Canteros A, Cannata Andía JB.
    Nephrol Dial Transplant; 1998 Jun 05; 13 Suppl 3():23-8. PubMed ID: 9568816
    [Abstract] [Full Text] [Related]

  • 6. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Barr J, Baillod RA.
    Arzneimittelforschung; 1994 Apr 05; 44(4):522-6. PubMed ID: 8011008
    [Abstract] [Full Text] [Related]

  • 7. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep 05; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 8. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ.
    Analyst; 1995 Mar 05; 120(3):845-51. PubMed ID: 7741239
    [Abstract] [Full Text] [Related]

  • 9. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.
    Brock JH, Licéaga J, Arthur HM, Kontoghiorghes GJ.
    Am J Hematol; 1990 May 05; 34(1):21-5. PubMed ID: 2327400
    [Abstract] [Full Text] [Related]

  • 10. Iron chelators induce apoptosis in proliferating cells.
    Hileti D, Panayiotidis P, Hoffbrand AV.
    Br J Haematol; 1995 Jan 05; 89(1):181-7. PubMed ID: 7833261
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ, Sheppard L, Hoffbrand AV, Charalambous J, Tikerpae J, Pippard MJ.
    J Clin Pathol; 1987 Apr 05; 40(4):404-8. PubMed ID: 3584483
    [Abstract] [Full Text] [Related]

  • 12. [Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells].
    González Suárez I, Fernández Martín JL, Naves Díaz M, Cannata Andía JB.
    Nefrologia; 2003 Apr 05; 23 Suppl 2():27-31. PubMed ID: 12778850
    [Abstract] [Full Text] [Related]

  • 13. High performance liquid chromatography methods for studying protein binding of aluminium in human serum in the absence and in the presence of desferrioxamine.
    García Alonso JI, López García A, Pérez Parajón J, Blanco González E, Sanz Medel A, Cannata JB.
    Clin Chim Acta; 1990 Jul 05; 189(1):69-79. PubMed ID: 2383920
    [Abstract] [Full Text] [Related]

  • 14. Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells.
    Chua AC, Ingram HA, Raymond KN, Baker E.
    Eur J Biochem; 2003 Apr 05; 270(8):1689-98. PubMed ID: 12694182
    [Abstract] [Full Text] [Related]

  • 15. The iron chelators desferrioxamine and 1-alkyl-2-methyl-3-hydroxypyrid-4-ones inhibit vascular prostacyclin synthesis in vitro.
    Jeremy JY, Kontoghiorghes GJ, Hoffbrand AV, Dandona P.
    Biochem J; 1988 Aug 15; 254(1):239-44. PubMed ID: 3140797
    [Abstract] [Full Text] [Related]

  • 16. Chemical, pharmacological, toxicological and therapeutic advances of deferiprone (L1) and other iron and aluminium chelators.
    Kontoghiorghes GJ.
    Arch Toxicol Suppl; 1996 Aug 15; 18():202-14. PubMed ID: 8678796
    [No Abstract] [Full Text] [Related]

  • 17. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 Aug 15; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 18. The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system.
    al-Rafaie FN, Wilkes S, Wonke B, Hoffbrand AV.
    Br J Haematol; 1994 May 15; 87(1):196-8. PubMed ID: 7947246
    [Abstract] [Full Text] [Related]

  • 19. Hydroxypyridinones and desferrioxamine inhibit macrophage-mediated LDL oxidation by iron but not by copper.
    Lamb DJ, Hider RC, Leake DS.
    Biochem Soc Trans; 1993 Aug 15; 21 ( Pt 3)(3):234S. PubMed ID: 8224391
    [No Abstract] [Full Text] [Related]

  • 20. Radiation sensitization of mammalian cells by metal chelators.
    Cook J.
    Radiat Res; 2001 Feb 15; 155(2):304-10. PubMed ID: 11175665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.